1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 
Comparison of clinical and demographic characteristics based on steal statusa and ischemic events
Steal StatusaP ValueIschemic EventsP Value
No Steal (n = 12)Steal (n = 25)No (n = 26)Yes (n = 11)
Age at baseline CVR (median) (IQR, 25–75) (yr)9.3 (5.6–14.5)10.8 (8.3–15).2810.9 (8.3–15)10.3 (7.2–12.5).44
Female (No.) (%)5 (41.7)16 (64).2914 (53.9)7 (63.6).72
Moyamoya classification (No.) (%).69.06
 Idiopathic4 (33.3)10 (40)7 (26.9)7 (63.6)
 Syndromicb8 (66.7)15 (60)19 (73.1)4 (36.4)
  NF12 (16.7)7 (28)7 (26.9)2 (18.2)
  Trisomy 21/other chromosomal disorders3 (25)4 (16)6 (23.1)1 (9.1)
  Sickle cell disease1 (8.3)4 (16)4 (15.4)1 (9.1)
  Postradiation vasculopathy2 (16.7)02 (7.7)0
Stroke (No.) (%)4 (33.3)8 (32)111 (42.3)1 (9.1).06
TIA (No.) (%)2 (16.7)6 (24)15 (19.2)3 (27.3).67
Seizure (No.) (%)2 (16.7)1 (4).242 (7.7)1 (9.1)1
Headaches (No.) (%)3 (25)5 (20)16 (23.1)2 (18.2)1
Asymptomatic (No.) (%)2 (16.7)4 (16)13 (11.5)3 (27.3).33
Others (No.) (%)02 (8.3).5402 (18.2).08
Moyamoya laterality (No.) (%).77.78
 Left3 (25)5 (20)6 (23.1)2 (18.2)
 Right1 (8.3)5 (20)5 (19.2)1 (9.1)
 Bilateral8 (66.7)15 (60)15 (57.7)8 (72.7)
  • Note:—NF1 indicates neurofibromatosis type 1.
  • ↵a Steal status before ischemic event occurrence or the end of follow-up.
  • ↵b Comorbidities falling under syndromic moyamoya are shown for informative purposes only and were not included in the inferential analysis.